• Nenhum resultado encontrado

Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies.

N/A
N/A
Protected

Academic year: 2017

Share "Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies."

Copied!
15
0
0

Texto

Loading

Imagem

Figure 1. Plasma concentrations of total PYY in Study 1 following 13 days of dosing GSK263, placebo or sitagliptin (A), and in Study 2 on Day 14 of co-dosing these study treatments with metformin (B)
Table 3. Glucose and peptide assays used in these studies.
Table 6. Percent change from baseline WM-AUC (0–24 h) for the gut peptides following repeat-dose administration in Studies 1 and 2.
Figure 3. Effects of GSK263 and sitagliptin on plasma total GIP. Plasma concentrations of total GIP in Study 1 following 13 days of dosing GSK263, placebo or sitagliptin (A), and in Study 2 on Day 14 of co-dosing these study treatments with metformin (B)
+3

Referências

Documentos relacionados

4.7 Application to composite volume elements This section presents a few examples of representative volume elements un- der different loading conditions and provides a better insight

Resumo As visões recentes sobre o mundo rural revelam grande permeabilidade à ideia de património como elemento estruturador de uma nova geração de estratégias e políticas

Nem as interpolações de raiz ptolomaica, nem a decomposição sub-regional de cada uma das nove unidades asiáticas pré-definidas perturbam o essencial da leitura proposta por

Na longa duração, a história da escola assentou em quatro combinatórias fundamentais (conhecimento científico, professor, didáctica, aluno), que são também os elementos

Popu- lation pharmacokinetics of liraglutide, a once-daily human glucagon-like peptide-1 analog, in healthy volunteers and subjects with type 2 diabetes, and comparison to

Altered gut microbiota Glucose utilization (Roux limb).

SHORT-TERM TREATMENT WITH METFORMIN IMPROVES THE CARDIOVASCULAR RISK PROFILE IN FIRST-DEGREE RELATIVES OF SUBJECTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE A METABOLIC SYNDROME

Metformin is associated with reduced risk of pancreatic cancer in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.. Diabetes Res